Capstone Holding Corp.

Equities

CAPS

US14068E2081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 08:10:00 2023-12-11 pm EST			5-day change	1st Jan Change
5.2 ^USD	-.--%		-.--%	-.--%

Apr. 01	Capstone Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Capstone Holding Corp. Announces Change in Board of Directors	CI

Capstone Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2018

March 22, 2019 at 04:02 pm EDT

Capstone Therapeutics Corp. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced operating loss was USD 181,000 compared to USD 1.680 million a year ago. Net loss was USD 380,000 compared to USD 1.755 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.04 a year ago.

Latest news about Capstone Holding Corp.

Capstone Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 31	CI
Capstone Holding Corp. Announces Change in Board of Directors	Dec. 29	CI
Capstone Holding Corp. Announces CFO Change	23-08-28	CI
Capstone Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Capstone Therapeutics Corp. announced that it has received $1.498 million in funding	21-04-05	CI
Capstone Therapeutics Corp. acquired an unknown stake Instone Co.	20-03-31	CI
Capstone Therapeutics Corp. entered into an agreement to acquire an unknown stake in Instone Co.	20-03-26	CI
Capstone Therapeutics Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-13	CI
Capstone Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-13	CI
Capstone Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-22	CI
Capstone Therapeutics Corp. Announces Executive Appointments	17-07-17	CI
Capstone Therapeutics Corp. announced that it expects to receive $1.01 million in funding	17-07-13	CI
Capstone Therapeutics Corp. Announces Resignation of Eric W. Fangmann from the Board of Directors and Audit Committee	16-03-18	CI
Capstone Therapeutics Corp. announced that it has received $1 million in funding from BVF Partners LP	16-02-02	CI
Capstone Therapeutics Corp. announced that it expects to receive $1 million in funding from BVF Partners LP	15-12-10	CI
Capstone Therapeutics Corp. and LipimetiX Development, Inc. Announce Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides	15-07-23	CI
Capstone Therapeutics Qualifies Fangmann to Serve on the Company’s Board	15-05-08	CI
Capstone Therapeutics Corp. Auditor Raises 'Going Concern' Doubt	15-03-15	CI
Capstone Therapeutics and LipimetiX Development Announce Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals	14-12-16	CI
Capstone Therapeutics Corp. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	14-11-13	CI
Capstone Therapeutics and LipimetiX Development, LLC Announce Phase 1A Results for AEM-28	14-09-02	CI
Capstone Therapeutics Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014	14-08-14	CI
Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects	14-06-11	CI
Lloyd Miller Recommends Nominee to the Board of Capstone Therapeutics	14-05-08	CI
Capstone Therapeutics and LipimetiX Development, LLC Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/Non-HDL Cholesterol Reduction	14-04-08	CI

Chart Capstone Holding Corp.

Duration

Period

More charts

Company Profile

Capstone Holding Corp. operates, through its wholly owned subsidiary, TotalStone, LLC, which is a construction materials company. TotalStone, LLC distributes masonry stone products for residential and commercial construction in the Midwest and Northeast United States. The Company, through its subsidiary, Capstone Beta, LLC, owns equity interest in Diamond Products, LLC, which is a sexual wellness products holding company. Diamond Products, LLC product portfolio includes adult toys, lingerie, games, lotions and creams that are sold globally in over 80 countries through 5,000 retailers as well as e-commerce Website.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CAPSTONE HOLDING CORP.	-.--%	820K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research